Pfizer discloses robust climate data with GHG Protocol alignment and SBTi validation, but progress is dire: only 15% of its 46% emissions reduction target achieved by 2024, renewable energy stuck at 14% despite RE100 membership, and hazardous waste flat since 2022. Critically, Pfizer's climate messaging is undermined by active membership in trade associations (US Chamber, NAM) that lobby against climate policy.
Same formula for every company. No curve. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Transparency & Accountability (7/10, 7/10). Weakest on Nature & Biodiversity Impact and Energy Source (3/10, 3/10).
12 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
8 of 12 sources are third-party verified or public record.
If you believe a source has been misread or a newer version exists, submit a challenge.
Among the 11 major healthcare / pharmaceuticals brands we've scored, Pfizer is tied =9th of 11, with 2 others.
Score history begins 4 April 2026.
As Pfizer's score updates, the trajectory will appear here.
We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
Pfizer is a US-based multinational pharmaceutical company founded in 1849, headquartered in New York City. With 78,500 employees and $63.6 billion in annual revenue, it ranks among the world's largest drug manufacturers. Pfizer develops vaccines, oncology treatments, primary care medicines, and specialty healthcare products across multiple therapeutic areas.
Pharma peer with similar scale; comparable emissions disclosure but divergent climate policy alignment.
View breakdown →Pharma peer; competing on ESG transparency and net-zero credibility; useful benchmark for sector standards.
View breakdown →Pharma peer; evaluate trade association consistency and renewable energy transition pace against Pfizer.
View breakdown →Pharma peer with overlapping footprint; assess water stress mitigation and biodiversity disclosure relative to Pfizer.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.